[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.238.190.122. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 336
Citations 0
Comment & Response
April 16, 2020

The Role of Maintenance Therapy in Metastatic Colorectal Cancer

Author Affiliations
  • 1Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, China
  • 2Department of Biostatistics, Zhongshan Hospital, Fudan University, Shanghai, China
JAMA Oncol. Published online April 16, 2020. doi:10.1001/jamaoncol.2020.0580

To the Editor In a systematic review and network meta-analysis, Sonbol and colleagues1 found that maintenance therapy was significantly associated with progression-free survival (PFS) but not overall survival (OS) compared with observation following first-line induction therapy for metastatic colorectal cancer. Additionally, all 3 maintenance strategies (fluoropyrimidine, bevacizumab, and fluoropyrimidine plus bevacizumab) significantly improved PFS but not OS compared with observation, whereas fluoropyrimidine and fluoropyrimidine plus bevacizumab ranked higher than bevacizumab in PFS and OS. However, we have some concerns regarding the methodological aspects of this work.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×